Epstein Secrets

sequencing. Earlier this year, I receiv=d the IFCC Award for Significant Contributions in Molecular Diagnostic=. I have been collaborating with Dr. Linnie Golightly of our Center for G=obal Health/Infectious Disease Division for the past decade, work=ng together closely to develop multiplexed PCR-LDR assays for

evices suitable f=r working in developing countries, and may be powered and run by a cell phone or smart device. • Current CDC approved EZ1-RT-P=R Taqman assay has LOD of 5,000 PFU/ml. This works when patient is&nbs=;febrile, i.e. has overt symptoms and may be contagious. • Next level of assay needs

sequencing. Earlier this year, I re=eived the IFCC Award for Significant Contributions in Molecular Diagn=stics. I have been collaborating with Dr. Linnie Golightly of our Center for =lobal Health/Infectious Disease Division for the past decade, wo=king together closely to develop multiplexed PCR-LDR assays for

ricated devices that w=ll allow for electronic detection, obviating the need for expens=ve hardware used in most fluorescent detection schemes (i.e. Taqman a=says). As such, we are poised to combine these technologie= for rapidly identifying and providing quantitative viral load fo= all the VHF, Variol

sequencing. Earlier this year, I receiv=d the IFCC Award for Significant Contributions in Molecular Diagnostic=. I have been collaborating with Dr. Linnie Golightly of our Center for G=obal Health/Infectious Disease Division for the past decade, work=ng together closely to develop multiplexed PCR-LDR assays for

devices suitable f=r working in developing countries, and may be powered and run by a cell phone or smart device. • Current CDC approved EZ1-RT-P=R Taqman assay has LOD of 5,000 PFU/ml. This works when patient is&nbs=;febrile, i.e. has overt symptoms and may be contagious. • Next level of assay needs